In an article published by The Scientist entitled ‘Microbes Play Role in Anti-Tumor Response’ it states that Gut microbiome composition can influence the effectiveness of cancer immunotherapy in mice.
We asked OptiBiotix’s CEO Stephen OHara for his thoughts on this who said: ‘These two studies provide further evidence of the link between the microbiome and response to cancer treatments. There is now a growing body of evidence supporting the role of the microbiome in the prevention, management, and treatment of a wide range of human diseases, either in isolation, or as partner treatments to enhance efficacy or reduce serious side affects. With over 500 US hospitals now offering microbiome treatments we will increasingly see microbiome modulation therapies entering mainstream clinical care in the next few years’.
The full article can be found at http://www.the-scientist.com/?articles.view/articleNo/44418/title/Microbes-Play-Role-in-Anti-Tumor-Response/
OptiBiotix Health Plc (LON:OPTI) was formed in March 2012 to develop compounds which modify the human microbiome – the collective genome of the microbes in the body – to prevent and manage human disease. The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
